First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients-Reference-Cited by-同舟云学术

First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients

Published:2018-02-22 Issue:6 Volume:38 Page:553-562
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Moiseyenko Vladimir M.,Moiseyenko Fedor V.,Yanus Grigoriy A.,Kuligina Ekatherina Sh.,Sokolenko Anna P.,Bizin Ilya V.,Kudriavtsev Alexey A.,Aleksakhina Svetlana N.,Volkov Nikita M.,Chubenko Vyacheslav A.,Kozyreva Kseniya S.,Kramchaninov Mikhail M.,Zhuravlev Alexandr S.,Shelekhova Kseniya V.,Pashkov Denis V.,Ivantsov Alexandr O.,Venina Aigul R.,Sokolova Tatyana N.,Preobrazhenskaya Elena V.,Mitiushkina Natalia V.,Togo Alexandr V.,Iyevleva Aglaya G.,Imyanitov Evgeny N.

Funder

Russian Foundation for Basic Research

Russian Science Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s40261-018-0629-1/fulltext.html

Reference31 articles.

1. Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol. 2014;20:899–907.

2. Shah U, Goldberg RM. Sequential versus combination therapy in the treatment of patients with advanced colorectal cancer. Clin Colorectal Cancer. 2008;7:315–20.